 PRS-220, an oral inhaled Anticalin protein targeting CTGF, a fully proprietary drug candidate for respiratory disease, is being developed as a local treatment for idiopathic pulmonary fibrosis Grant to enable the evaluation of PRS-220 for the treatment of post-COVID-19-related pulmonary fibrosis for clinical-readiness in general and initial clinical development of PRS-220 in the post-COVID-19 setting Clinical development of PRS-220 expected to begin in 2022 BOSTON, MA ACCESSWIRE June 25, 2021 Pieris Pharmaceuticals, Inc. NASDAQ:PIRS, a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin technology platform for respiratory diseases, cancer, and other indications, today announced the development of PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor CTGF, also known as CCN2, for the treatment of idiopathic pulmonary fibrosis IPF. The Company also announced it has been selected to receive a 14.2 million euro approximately 17 million USD grant from the Bavarian Ministry of Economic Affairs, Regional Development and Energy for the research and development of PRS-220 for post-acute sequelae of SARS-CoV-2 infection PASC pulmonary fibrosis PASC-PF, also known as post-COVID-19 syndrome pulmonary fibrosis or long COVID. 